Search

FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD

COVID-19: Boehringer Ingelheim steps up effort with Global Support Program

Supporting People with Diabetes and Related Conditions in the Time of COVID-19

Creating an Inclusive Workplace for Employees with Disabilities

OFEV® (nintedanib) Data in Patients with ILDs | Boehringer Ingelheim US

Studies from American Thoracic Society Congress show the proportion of patients with 10% or greater declines in lung function were lower in the OFEV group.

Rising Star Leads with Determination | Boehringer Ingelheim US

Click to find out more on our partnership with the HBA, where we honor a BI colleague as a “Rising Star” to support the advancement of women in health care.

New analysis supports long-term treatment with Ofev® in SSc-ILD patients

Yankees Legend Bernie Williams Teams Up With Multi-Platinum Recording Artist and Actress Jordin Sparks to Unveil New Song Featuring Lyrics From The Breathless® Ballad Challenge Winner

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark

Employees compassionately help local communities with country-wide food drive

Coming together to bring food to people in need

Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection

Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

FDA accepts sNDA for children/adolescents with fibrosing ILD

U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease

Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk — in honor of her mom

Boehringer Ingelheim announces nintedanib expanded access program (EAP) for children and adolescents with fibrosing interstitial lung disease

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fraction

Our goal of transforming DLL3-positive carcinomas

Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers